Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Impax Laboratories Inc (NASDAQ:IPXL)

12.85
Delayed Data
As of Mar 29
 +0.05 / +0.39%
Today’s Change
7.75
Today|||52-Week Range
37.20
-3.02%
Year-to-Date
Impax Gains 38% On CEO Appointment, Talk of Sale
Mar 27 / TheStreet.com - Paid Partner Content
Skincare Makers Lead Biotech Movers
Mar 27 / TheStreet.com - Paid Partner Content
Mid-Morning Market Update: Markets Open Lower; G-III Apparel Misses Q4 Views
Mar 27 / Benzinga - Paid Partner Content
Falling Earnings Estimates Signal Weakness Ahead for Impax Laboratories (IPXL)
Mar 22 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close12.80
Today’s open12.80
Day’s range12.45 - 12.93
Volume3,220,918
Average volume (3 months)1,836,543
Market cap$944.0M
Dividend yield--
Data as of 4:14pm ET, 03/29/2017

Growth & Valuation

Earnings growth (last year)-1,327.78%
Earnings growth (this year)-31.83%
Earnings growth (next 5 years)+7.00%
Revenue growth (last year)-4.19%
P/E ratioNM
Price/Sales1.14
Price/Book1.51

Competitors

 Today’s
change
Today’s
% change
DEPODepomed Inc-0.44-3.09%
ZIOPZIOPHARM Oncology In...+0.07+1.06%
FLXNFlexion Therapeutics...-0.51-1.86%
AKAOAchaogen Inc+1.79+7.49%
Data as of 3:59pm ET, 03/29/2017

Financials

Next reporting dateMay 3, 2017
EPS forecast (this quarter)$0.14
Annual revenue (last year)$824.4M
Annual profit (last year)-$472.0M
Net profit margin-57.26%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
J. Kevin Buchi
Senior Vice President-
Global Operations
Andrew Schaschl
Corporate headquarters
Hayward, California

Forecasts


Search for Jobs